Recent research suggests a substantial reduction in greenhouse gas emissions with de-escalation per cancer patient
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy
The first results from two phase III studies of Ra-223 and 177Lu-PNT2002 may help to decipher their role in the treatment of patients with mCRPC
Final late-phase trial results show that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients
Results from early-phase studies reveal potential for a new cancer vaccine and adaptive immunotherapy
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.